SUNSHINE BIOPHARMA INC (SBFM) Stock News

USA - NASDAQ:SBFM - US8677817004 - Common Stock

1.98 USD

-0.11 (-5.26%)

Last: 10/20/2025, 11:40:35 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SBFM Latest News, Press Relases and Analysis

All

Press Releases

4 hours ago - By: ACCESS Newswire

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

4 days ago - By: Stocktwits

News Image

Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit

4 days ago - By: Benzinga

Sunshine Biopharma Stock Is Surging Thursday: Here's What's Happening

4 days ago - By: Benzinga - Mentions: ADAP GNPX HYPR PRAX ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

4 days ago - By: ACCESS Newswire

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

6 days ago - By: ACCESS Newswire

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

6 days ago - By: ACCESS Newswire

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

6 days ago - By: ACCESS Newswire

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

11 days ago - By: ACCESS Newswire

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

4 months ago - By: Stocktwits

Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In

4 months ago - By: ACCESS Newswire

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

4 months ago - By: Stocktwits

Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’

4 months ago - By: ACCESS Newswire

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

5 months ago - By: ACCESS Newswire

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

6 months ago - By: ACCESS Newswire

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

6 months ago - By: Stocktwits

Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug

6 months ago - By: ACCESS Newswire

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

7 months ago - By: ACCESS Newswire

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

7 months ago - By: ACCESS Newswire

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

7 months ago - By: ACCESS Newswire

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

7 months ago - By: ACCESS Newswire

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

7 months ago - By: ACCESS Newswire

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

7 months ago - By: ACCESS Newswire

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

9 months ago - By: ACCESS Newswire

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT